Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
종목 코드 ASRT
회사 이름Assertio Holdings Inc
상장일Feb 12, 1997
CEOReisenauer (Mark L)
직원 수58
유형Ordinary Share
회계 연도 종료Feb 12
주소100 S. Saunders Road
도시LAKE FOREST
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호60045
전화12244197106
웹사이트https://www.assertiotx.com/
종목 코드 ASRT
상장일Feb 12, 1997
CEOReisenauer (Mark L)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음